Pfizer enters talks to buy Seagen for over $30 billion, says report

Deal will help the firm add to its line-up of cancer treatments

Pfizer is in talks to acquire biotech Seagen according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies, The Wall Street Journal reported.

The talks are at an early stage and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal.  If there is a deal, it would be big: Seagen has a market value of some $30 billion and would be expected